Abstract

The receptor for advanced glycation end products (RAGE) and its downstream pathways are involved in various inflammatory and immune responses. Importantly, there is soluble RAGE (sRAGE) that forms either by alternative splicing of RAGE messenger ribonucleic acid as the endogenous soluble form of RAGE (esRAGE) or by proteolytic cleavage of full-length RAGE protein. This study aimed to investigate the associations of the plasma levels of sRAGE and esRAGE in ischemic stroke (IS) patients with and without dementia. This cross-sectional study recruited patients with IS at a university medical center. Vascular dementia was defined as the scale of Clinical Dementia Ranking (CDR) ≥ 1. Standard enzyme-linked immunosorbent assay was used to measure the plasma concentration of sRAGE and esRAGE. From November 2014 to October 2015, a total of 172 IS patients (mean age: 72.1 ± 7.5 years, 64.5% male) were recruited, including 73 with CDR = 0, 63 with CDR = 0.5, and 36 with CDR ≥ 1. In univariate analysis, IS patients with dementia were older and had more diabetes mellitus, less atrial fibrillation, and higher post-stroke modified Rankin Scale scores than those without dementia. Plasma levels of sRAGE and esRAGE were significantly higher in IS patients with than those without dementia (1.44 ± 1.29 vs. 1.03 ± 0.48 and 0.39 ± 0.40 vs. 0.24 ± 0.13 ng/mL, both p < 0.01). Importantly, both parameters remained independent after adjustment for clinical variables (OR 2.683, p = 0.013 and OR 39.192, p = 0.006, respectively). In summary, plasma sRAGE and esRAGE were elevated in those with dementia compared with those without dementia among IS patients.

Original languageEnglish
Pages (from-to)579-583
Number of pages5
JournalNeuroMolecular Medicine
Volume19
Issue number4
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Dementia
Stroke
Advanced Glycosylation End Product-Specific Receptor
Vascular Dementia
Alternative Splicing
Atrial Fibrillation
Diabetes Mellitus
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay
RNA
Proteins

Keywords

  • esRAGE
  • Ischemic stroke
  • sRAGE
  • Vascular dementia

ASJC Scopus subject areas

  • Molecular Medicine
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

Elevated Plasma Level of Soluble Form of RAGE in Ischemic Stroke Patients with Dementia. / Tang, Sung Chun; Yang, Kai Chien; Hu, Chaur Jong; Chiou, Hung Yi; Wu, Chau Chung; Jeng, Jiann Shing.

In: NeuroMolecular Medicine, Vol. 19, No. 4, 01.12.2017, p. 579-583.

Research output: Contribution to journalArticle

Tang, Sung Chun ; Yang, Kai Chien ; Hu, Chaur Jong ; Chiou, Hung Yi ; Wu, Chau Chung ; Jeng, Jiann Shing. / Elevated Plasma Level of Soluble Form of RAGE in Ischemic Stroke Patients with Dementia. In: NeuroMolecular Medicine. 2017 ; Vol. 19, No. 4. pp. 579-583.
@article{d3fc2ff414c74c6b895165a77b404129,
title = "Elevated Plasma Level of Soluble Form of RAGE in Ischemic Stroke Patients with Dementia",
abstract = "The receptor for advanced glycation end products (RAGE) and its downstream pathways are involved in various inflammatory and immune responses. Importantly, there is soluble RAGE (sRAGE) that forms either by alternative splicing of RAGE messenger ribonucleic acid as the endogenous soluble form of RAGE (esRAGE) or by proteolytic cleavage of full-length RAGE protein. This study aimed to investigate the associations of the plasma levels of sRAGE and esRAGE in ischemic stroke (IS) patients with and without dementia. This cross-sectional study recruited patients with IS at a university medical center. Vascular dementia was defined as the scale of Clinical Dementia Ranking (CDR) ≥ 1. Standard enzyme-linked immunosorbent assay was used to measure the plasma concentration of sRAGE and esRAGE. From November 2014 to October 2015, a total of 172 IS patients (mean age: 72.1 ± 7.5 years, 64.5{\%} male) were recruited, including 73 with CDR = 0, 63 with CDR = 0.5, and 36 with CDR ≥ 1. In univariate analysis, IS patients with dementia were older and had more diabetes mellitus, less atrial fibrillation, and higher post-stroke modified Rankin Scale scores than those without dementia. Plasma levels of sRAGE and esRAGE were significantly higher in IS patients with than those without dementia (1.44 ± 1.29 vs. 1.03 ± 0.48 and 0.39 ± 0.40 vs. 0.24 ± 0.13 ng/mL, both p < 0.01). Importantly, both parameters remained independent after adjustment for clinical variables (OR 2.683, p = 0.013 and OR 39.192, p = 0.006, respectively). In summary, plasma sRAGE and esRAGE were elevated in those with dementia compared with those without dementia among IS patients.",
keywords = "esRAGE, Ischemic stroke, sRAGE, Vascular dementia",
author = "Tang, {Sung Chun} and Yang, {Kai Chien} and Hu, {Chaur Jong} and Chiou, {Hung Yi} and Wu, {Chau Chung} and Jeng, {Jiann Shing}",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s12017-017-8471-9",
language = "English",
volume = "19",
pages = "579--583",
journal = "NeuroMolecular Medicine",
issn = "1535-1084",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Elevated Plasma Level of Soluble Form of RAGE in Ischemic Stroke Patients with Dementia

AU - Tang, Sung Chun

AU - Yang, Kai Chien

AU - Hu, Chaur Jong

AU - Chiou, Hung Yi

AU - Wu, Chau Chung

AU - Jeng, Jiann Shing

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The receptor for advanced glycation end products (RAGE) and its downstream pathways are involved in various inflammatory and immune responses. Importantly, there is soluble RAGE (sRAGE) that forms either by alternative splicing of RAGE messenger ribonucleic acid as the endogenous soluble form of RAGE (esRAGE) or by proteolytic cleavage of full-length RAGE protein. This study aimed to investigate the associations of the plasma levels of sRAGE and esRAGE in ischemic stroke (IS) patients with and without dementia. This cross-sectional study recruited patients with IS at a university medical center. Vascular dementia was defined as the scale of Clinical Dementia Ranking (CDR) ≥ 1. Standard enzyme-linked immunosorbent assay was used to measure the plasma concentration of sRAGE and esRAGE. From November 2014 to October 2015, a total of 172 IS patients (mean age: 72.1 ± 7.5 years, 64.5% male) were recruited, including 73 with CDR = 0, 63 with CDR = 0.5, and 36 with CDR ≥ 1. In univariate analysis, IS patients with dementia were older and had more diabetes mellitus, less atrial fibrillation, and higher post-stroke modified Rankin Scale scores than those without dementia. Plasma levels of sRAGE and esRAGE were significantly higher in IS patients with than those without dementia (1.44 ± 1.29 vs. 1.03 ± 0.48 and 0.39 ± 0.40 vs. 0.24 ± 0.13 ng/mL, both p < 0.01). Importantly, both parameters remained independent after adjustment for clinical variables (OR 2.683, p = 0.013 and OR 39.192, p = 0.006, respectively). In summary, plasma sRAGE and esRAGE were elevated in those with dementia compared with those without dementia among IS patients.

AB - The receptor for advanced glycation end products (RAGE) and its downstream pathways are involved in various inflammatory and immune responses. Importantly, there is soluble RAGE (sRAGE) that forms either by alternative splicing of RAGE messenger ribonucleic acid as the endogenous soluble form of RAGE (esRAGE) or by proteolytic cleavage of full-length RAGE protein. This study aimed to investigate the associations of the plasma levels of sRAGE and esRAGE in ischemic stroke (IS) patients with and without dementia. This cross-sectional study recruited patients with IS at a university medical center. Vascular dementia was defined as the scale of Clinical Dementia Ranking (CDR) ≥ 1. Standard enzyme-linked immunosorbent assay was used to measure the plasma concentration of sRAGE and esRAGE. From November 2014 to October 2015, a total of 172 IS patients (mean age: 72.1 ± 7.5 years, 64.5% male) were recruited, including 73 with CDR = 0, 63 with CDR = 0.5, and 36 with CDR ≥ 1. In univariate analysis, IS patients with dementia were older and had more diabetes mellitus, less atrial fibrillation, and higher post-stroke modified Rankin Scale scores than those without dementia. Plasma levels of sRAGE and esRAGE were significantly higher in IS patients with than those without dementia (1.44 ± 1.29 vs. 1.03 ± 0.48 and 0.39 ± 0.40 vs. 0.24 ± 0.13 ng/mL, both p < 0.01). Importantly, both parameters remained independent after adjustment for clinical variables (OR 2.683, p = 0.013 and OR 39.192, p = 0.006, respectively). In summary, plasma sRAGE and esRAGE were elevated in those with dementia compared with those without dementia among IS patients.

KW - esRAGE

KW - Ischemic stroke

KW - sRAGE

KW - Vascular dementia

UR - http://www.scopus.com/inward/record.url?scp=85032930784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032930784&partnerID=8YFLogxK

U2 - 10.1007/s12017-017-8471-9

DO - 10.1007/s12017-017-8471-9

M3 - Article

VL - 19

SP - 579

EP - 583

JO - NeuroMolecular Medicine

JF - NeuroMolecular Medicine

SN - 1535-1084

IS - 4

ER -